A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy

Heart

Volumn 99, Issue 8, 2013, Pages 534-541

  O'Mahony, Constantinos ^a,b   Tome Esteban, Maite ^a   Lambiase, Pier D ^a   Pantazis, Antonios ^a   Dickie, Shaughan ^a   McKenna, William J ^a   Elliott, Perry M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABNORMAL BLOOD PRESSURE RESPONSE TO EXERCISE; ADULT; ARTICLE; BLOOD PRESSURE; COHORT ANALYSIS; FAINTNESS; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONSUSTAINED VENTRICULAR TACHYCARDIA; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH; VALIDATION STUDY;

ADULT; ALGORITHMS; AMERICAN HEART ASSOCIATION; CARDIOMYOPATHY, HYPERTROPHIC; CRITICAL PATHWAYS; DEATH, SUDDEN, CARDIAC; DECISION SUPPORT TECHNIQUES; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; EQUIPMENT FAILURE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONDON; MALE; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SOCIETIES, MEDICAL; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84875274402     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-303271     Document Type: Article

References (43)

1. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858-64.
2. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006;92:785-91. (Pubitemid 43799212)
3. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-18.
4. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/ European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-91.
5. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: executive summary: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:2761-96.
6. O'Mahony C, Lambiase PD, Quarta G, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart 2012;98:116-25.
7. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008;29:270-6.
8. McKenna WJ, Spirito P, Desnos M, et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997;77:130-2. (Pubitemid 27115795)
9. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987-91. (Pubitemid 27500099)
10. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-41. (Pubitemid 44297366)
11. Gimeno JR, Tome-Esteban M, Lofiego C, et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009;30:2599-605.
12. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44. (Pubitemid 30422619)
13. Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ 1994;309:102. (Pubitemid 24216428)
14. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36. (Pubitemid 12142173)
15. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322-4. (Pubitemid 10040022)
16. Begley DA, Mohiddin SA, Tripodi D, et al. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003;26:1887-96. (Pubitemid 37130061)
17. Lin G, Nishimura RA, Gersh BJ, et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 2009;95:709-14.
18. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter- defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405-12. (Pubitemid 47124061)
19. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998;31:1081-5.
20. Woo A, Monakier D, Harris L, et al. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart 2007;93:1044-5. (Pubitemid 47310979)
21. Kaski PJ, Tome Esteban MT, Lowe M, et al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart 2007;93:372-4. (Pubitemid 46579536)
22. Marin F, Gimeno JR, Paya E, et al. The implantable cardioverter- defibrillator and hypertrophic cardiomyopathy. Experience at three centers. Rev Esp Cardiol 2006;59:537-44. (Pubitemid 44203197)
23. Syska P, Przybylski A, Chojnowska L, et al. Implantable cardioverter-defibrillator in patients With hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol 2010;21:883-9.
24. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. 1 edn. Springer-Verlag, New York, USA, 2001.
25. Christiaans I, van Engelen K, van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace 2010;12:313-21.
26. Germano JJ, Reynolds M, Essebag V, et al. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol 2006;97:1255-61.
27. Elliott PM, Gimeno B Jr., Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357:420-4. (Pubitemid 32156140)
28. Dimitrow PP, Chojnowska L, Rudzinski T, et al. Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. Eur Heart J 2010;31:3084-93.
29. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. Circulation 2012;125:1043-52.
30. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010;363:36-44.
31. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
32. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82. (Pubitemid 351977019)
33. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:2044-51.
34. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009;119:1703-10.
35. D'Andrea A, Caso P, Severino S, et al. Prognostic value of intra-left ventricular electromechanical asynchrony in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1311-18. (Pubitemid 43998104)
36. Dimitrow PP, Dubiel JS. Echocardiographic risk factors predisposing to sudden cardiac death in hypertrophic cardiomyopathy. Heart 2005;91:93-4. (Pubitemid 39665005)
37. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 1998;82:774-8.
38. Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:206-11. (Pubitemid 29064094)
39. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85. (Pubitemid 30390237)
40. Kofflard MJM, Ten Cate FJ, van der Lee C, et al. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003;41:987-93. (Pubitemid 36315542)
41. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873-9. (Pubitemid 37059747)
42. Green JJ, Berger JS, Kramer CM, et al. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012;5:370-7.
43. Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470-6. (Pubitemid 41040288)